UFP (UFPT) 10-Q 9 Aug 22 2022 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 02, 2022
Document Information [Line Items]
Entity Central Index Key	0000914156
Entity Registrant Name	UFP TECHNOLOGIES INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-12648
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2314970
Entity Address, Address Line One	100 Hale Street
Entity Address, City or Town	Newburyport
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01950
City Area Code	978
Local Phone Number	352-2200
Title of 12(b) Security	Common Stock
Trading Symbol	UFPT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,566,531

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 5,576	$ 11,117
Receivables, net	57,913	39,384
Inventories	50,556	33,436
Prepaid expenses and other current assets	11,552	3,383
Refundable income taxes	102	0
Total current assets	125,699	87,320
Property, plant and equipment	137,443	126,837
Less accumulated depreciation and amortization	(71,325)	(70,268)
Net property, plant and equipment	66,118	56,569
Goodwill	114,921	107,905
Intangible assets, net	70,514	67,585
Non-qualified deferred compensation plan	4,008	4,327
Finance lease right of use assets	241	271
Operating lease right of use assets	12,420	9,053
Other assets	1,130	1,102
Total assets	395,051	334,132
Current liabilities:
Accounts payable	23,443	10,611
Accrued expenses	17,928	12,700
Deferred revenue	5,612	4,247
Finance lease liabilities	58	58
Operating lease liabilities	2,341	2,181
Income taxes payable	0	909
Current installments of long-term debt	4,000	4,000
Total current liabilities	53,382	34,706
Long-term debt, excluding current installments	96,000	71,000
Deferred income taxes	3,329	3,263
Non-qualified deferred compensation plan	4,054	4,337
Finance lease liabilities	186	215
Operating lease liabilities	10,229	6,903
Other liabilities	20,581	19,262
Total liabilities	187,761	139,686
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized; no shares issued	0	0
Common stock, $.01 par value, 20,000,000 shares authorized; 7,596,090 and 7,566,531 shares issued and outstanding, respectively, at June 30, 2022; 7,564,645 and 7,535,086 shares issued and outstanding, respectively, at December 31, 2021	76	75
Additional paid-in capital	34,342	34,151
Retained earnings	174,594	160,807
Accumulated other comprehensive loss	(1,135)	0
Treasury stock at cost: 29,559 shares at June 30, 2022 and 29,559 shares at December 31, 2021	(587)	(587)
Total stockholders’ equity	207,290	194,446
Total liabilities and stockholders' equity	$ 395,051	$ 334,132

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	7,596,090	7,564,645
Common stock, shares outstanding (in shares)	7,566,531	7,535,086
Treasury stock, shares (in shares)	29,559	29,559

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net sales	$ 94,343	$ 50,655	$ 165,585	$ 99,254
Cost of sales	70,019	37,241	124,128	73,231
Gross profit	24,324	13,414	41,457	26,023
Selling, general & administrative expenses	12,078	7,228	22,088	14,538
Acquisition costs	242	0	1,017	0
Change in fair value of contingent consideration	6,002	0	6,002	0
Gain on sale of property, plant & equipment	(6,197)	(21)	(6,209)	(21)
Operating income	12,199	6,207	18,559	11,506
Interest income	(11)	(21)	(23)	(5)
Interest expense	744	0	1,083	0
Other (income) expenses	(157)	4	(209)	(7)
Income before income tax expense	11,623	6,224	17,708	11,518
Income tax expense	2,694	1,509	3,921	2,640
Net income	$ 8,929	$ 4,715	$ 13,787	$ 8,878
Net income per share:
Basic (in dollars per share)	$ 1.18	$ 0.63	$ 1.83	$ 1.18
Diluted (in dollars per share)	$ 1.17	$ 0.62	$ 1.81	$ 1.17
Weighted average common shares outstanding:
Basic (in shares)	7,563	7,527	7,554	7,517
Diluted (in shares)	7,608	7,573	7,618	7,575
Comprehensive Income
Net income	$ 8,929	$ 4,715	$ 13,787	$ 8,878
Other comprehensive income:
Foreign currency translation adjustment	(1,516)	0	(1,135)	0
Other comprehensive loss	(1,516)	0	(1,135)	0
Comprehensive income	$ 7,413	$ 4,715	$ 12,652	$ 8,878

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock Outstanding [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2020	7,500				30
Balance at Dec. 31, 2020	$ 75	$ 32,484	$ 144,921	$ 0	$ (587)	$ 176,893
Share-based compensation (in shares)	34				0
Share-based compensation	$ 0	501	0	0	$ 0	501
Net share settlement of RSUs (in shares)	(14)				0
Net share settlement of RSUs	$ 0	(738)	0	0	$ 0	(738)
Net income	$ 0	0	4,163		$ 0	4,163
Balance (in shares) at Mar. 31, 2021	7,520				30
Balance at Mar. 31, 2021	$ 75	32,247	149,084	0	$ (587)	180,819
Balance (in shares) at Dec. 31, 2020	7,500				30
Balance at Dec. 31, 2020	$ 75	32,484	144,921	0	$ (587)	176,893
Other comprehensive income						0
Net income						8,878
Other comprehensive loss						0
Balance (in shares) at Jun. 30, 2021	7,531				30
Balance at Jun. 30, 2021	$ 75	33,027	153,799	0	$ (587)	186,314
Balance (in shares) at Mar. 31, 2021	7,520				30
Balance at Mar. 31, 2021	$ 75	32,247	149,084	0	$ (587)	180,819
Share-based compensation (in shares)	4				0
Share-based compensation	$ 0	620	0	0	$ 0	620
Net share settlement of RSUs	0	(2)	0	0	0	(2)
Other comprehensive income						0
Net income	$ 0	0	4,715	0	$ 0	4,715
Exercise of stock options (in shares)	7				0
Exercise of stock options	$ 0	162	0	0	$ 0	162
Other comprehensive loss						0
Balance (in shares) at Jun. 30, 2021	7,531				30
Balance at Jun. 30, 2021	$ 75	33,027	153,799	0	$ (587)	186,314
Balance (in shares) at Dec. 31, 2021	7,535				30
Balance at Dec. 31, 2021	$ 75	34,151	160,807	0	$ (587)	194,446
Share-based compensation (in shares)	46				0
Share-based compensation	$ 1	691	0	0	$ 0	692
Net share settlement of RSUs (in shares)	(20)				0
Net share settlement of RSUs	$ 0	(1,299)	0	0	$ 0	(1,299)
Other comprehensive income	0	0	0	381	0	381
Net income	0	0	4,858		0	4,858
Other comprehensive loss	$ 0	0	0	381	$ 0	381
Balance (in shares) at Mar. 31, 2022	7,561				30
Balance at Mar. 31, 2022	$ 76	33,543	165,665	381	$ (587)	199,078
Balance (in shares) at Dec. 31, 2021	7,535				30
Balance at Dec. 31, 2021	$ 75	34,151	160,807	0	$ (587)	194,446
Other comprehensive income						(1,135)
Net income						13,787
Other comprehensive loss						(1,135)
Balance (in shares) at Jun. 30, 2022	7,566				30
Balance at Jun. 30, 2022	$ 76	34,342	174,594	(1,135)	$ (587)	207,290
Balance (in shares) at Mar. 31, 2022	7,561				30
Balance at Mar. 31, 2022	$ 76	33,543	165,665	381	$ (587)	199,078
Share-based compensation (in shares)	4				0
Share-based compensation	$ 0	781	0	0	$ 0	781
Net share settlement of RSUs	0	(3)	0	0	0	(3)
Other comprehensive income	0	0	0	(1,516)	0	(1,516)
Net income	$ 0	0	8,929		$ 0	8,929
Exercise of stock options (in shares)	1				0
Exercise of stock options	$ 0	21	0	0	$ 0	21
Other comprehensive loss	$ 0	0	0	(1,516)	$ 0	(1,516)
Balance (in shares) at Jun. 30, 2022	7,566				30
Balance at Jun. 30, 2022	$ 76	$ 34,342	$ 174,594	$ (1,135)	$ (587)	$ 207,290

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) $ in Thousands, € in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)
Cash flows from operating activities:
Net income	$ 13,787	$ 8,878
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	6,333	4,172
Gain on disposal of property, plant & equipment	(6,209)	(21)
Share-based compensation	1,473	1,121
Interest expense on finance leases	3	1
Deferred income taxes	(383)	383
Change in fair value of contingent consideration	6,002	0
Changes in operating assets and liabilities:
Receivables, net	(16,363)	(4,794)
Inventories	(15,212)	(2,518)
Prepaid expenses and other current assets	(1,320)	(397)
Refundable income taxes	(1,103)	(870)
Other assets	(3,004)	(168)
Accounts payable	11,832	4,032
Accrued expenses	4,594	248
Deferred revenue	1,365	16
Non-qualified deferred compensation plan and other liabilities	(1,830)	(196)
Net cash (used in) provided by operating activities	(35)	9,887
Cash flows from investing activities:
Additions to property, plant, and equipment	(8,502)	(3,282)
Proceeds from sale of fixed assets	12	21
Net cash used in investing activities	(29,143)	(3,261)
Cash flows from financing activities:
Proceeds from advances on revolving line of credit	34,000	0
Payments on revolving line of credit	(7,000)	0
Principal payments of long-term debt	(2,000)	0
Principal payments on finance lease obligations	(32)	(9)
Proceeds from exercise of stock options	21	162
Payment of statutory withholdings for restricted stock units vested	(1,302)	(740)
Net cash provided by (used in) financing activities	23,687	(587)
Effect of foreign currency exchange rates on cash and cash equivalents	(50)	0
Net (decrease) increase in cash and cash equivalents	(5,541)	6,039
Cash and cash equivalents at beginning of period	11,117	24,234
Cash and cash equivalents at end of period	5,576	30,273
Advant Medical [Member]
Cash flows from investing activities:
Acquisition, net of cash acquired	(20,768)	0
DAS Medical [Member]
Cash flows from investing activities:
Acquisition, net of cash acquired	$ 115	$ 0

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	( 1 Basis of Presentation The interim condensed consolidated financial statements of UFP Technologies, Inc. (the “Company”) presented herein, have been prepared pursuant to the rules of the Securities and Exchange Commission for quarterly reports on Form 10 not December 31, 2021, 2021 10 The condensed consolidated balance sheets as of June 30, 2022 December 31, 2021, three six June 30, 2022 2021, three six June 30, 2022 2021, six June 30, 2022 2021 December 31, 2021 not The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three six June 30, 2022 not December 31, 2022. New Accounting Policy The Company translates all assets and liabilities of its foreign subsidiaries, where the U.S. dollar is not not Recent Accounting Pronouncements There are no

Note 2 - Acquisitions

Note 2 - Acquisitions	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Business Combination Disclosure [Text Block]	( 2 Acquisitions Advant Medical On March 16, 2022, €19.0 Founded in 1993, The following table summarizes the allocation of consideration paid to the acquisition date fair value of the assets acquired and liabilities assumed based on management’s preliminary estimates of fair value (in thousands): Fair value of considerations transferred Cash paid at closing $ 23,608 Other liability 395 Cash from Advant (2,840 ) Total consideration $ 21,163 Purchase price allocation Accounts receivable $ 2,299 Inventory 2,410 Other current assets 213 Property, plant, and equipment 5,704 Customer contracts & relationships 2,925 Intellectual property 2,127 Non-compete agreement 259 Lease right of use assets 289 Other assets 42 Goodwill 7,139 Total identifiable assets $ 23,407 Accounts payable (772 ) Accrued expenses (668 ) Income taxes (66 ) Deferred taxes (449 ) Lease liabilities (289 ) Net assets acquired $ 21,163 Acquisition costs associated with the transaction were approximately $779 thousand, of which $749 thousand was charged to expense in the six June 30, 2022 December 31, 2021. The amount of revenue and earnings of Advant recognized since the acquisition date, which is included in the condensed consolidated statement of income for the period ended June 30, 2022, Pro-forma statements The following table contains an unaudited pro forma condensed consolidated statement of operations for the six June 30, 2022 2021 three June 30, 2021, Three Months Ended June 30, Six Months Ended June 30, 2021 2022 2021 (Unaudited) (Unaudited) (Unaudited) Sales $ 56,203 $ 169,812 $ 110,079 Operating Income $ 6,666 $ 19,302 $ 12,663 Net Income $ 5,027 $ 14,341 $ 9,666 Earnings per share: Basic $ 0.67 $ 1.90 $ 1.29 Diluted $ 0.66 $ 1.88 $ 1.28 The above unaudited pro forma information is presented for illustrative purposes only and may not may DAS Medical On December 22, 2021 may four In connection with its entry into the Purchase Agreement, the Company also entered into an Agreement for the Purchase and Sale of Personal Goodwill (the “Goodwill Agreement”) with the purchase price beneficiaries. Pursuant to the terms of the Goodwill Agreement, on December 22, 2021, The Company has also entered into Non-Competition Agreements with the beneficiaries and the Company has agreed to pay additional consideration to the parties to the Non-Competition Agreements, including an aggregate of $10.0 million in payments over the ten Founded in 2010, The following table summarizes the allocation of consideration paid to the acquisition date fair value of the assets acquired and liabilities assumed based on management’s preliminary estimates of fair value (in thousands): Cash paid at closing $ 95,000 Contingent liability (Earn-out) 5,188 Non-compete agreements 8,855 Cash from DAS (8,316 ) Working capital adjustment (115 ) Total consideration $ 100,612 Purchase price allocation Accounts receivable $ 2,351 Inventory 7,570 Other current assets 68 Property, plant, and equipment 3,314 Customer contracts & relationships 36,730 Intellectual property 2,380 Non-compete agreement 4,697 Lease right of use assets 1,221 Goodwill 51,985 Total identifiable assets $ 110,316 Accounts payable (5,238 ) Accrued expenses (3,238 ) Deferred revenue (7 ) Lease liabilities (1,221 ) Net assets acquired $ 100,612 Acquisition costs associated with the transaction were approximately $448 thousand, of which $155 thousand were charged to expense in the six June 30, 2022 December 31, 2021. Contech Medical On October 12, 2021, 12 June 30, 2022. Founded in 1987, five one five The following table summarizes the allocation of consideration paid to the acquisition date fair value of the assets acquired and liabilities assumed based on management’s estimates of fair value (in thousands): Fair value of considerations transferred Cash paid at closing $ 9,766 Contingent liability (Earn-out) 4,543 Other liability 500 Cash from Contech (266 ) Total consideration $ 14,543 Purchase price allocation Accounts receivable $ 2,851 Inventory 2,320 Other current assets 37 Property, plant, and equipment 1,170 Customer contracts & relationships 3,043 Intellectual property 2,247 Non-compete agreement 86 Lease right of use assets 1,523 Goodwill 4,278 Total identifiable assets $ 17,555 Accounts payable (1,015 ) Accrued expenses (414 ) Deferred revenue (60 ) Lease liabilities (1,523 ) Net assets acquired $ 14,543 Acquisition costs associated with the transaction were approximately $153 thousand, of which $113 thousand were charged to expense in the six June 30, 2022 December 31, 2021. Pro-forma statements The following table contains an unaudited pro forma condensed consolidated statement of operations for the three six June 30, 2021, Three-month Period Ended June 30, 2021 Six-month Period Ended June 30, 2021 (Unaudited) (Unaudited) Sales $ 68,741 $ 132,603 Operating income $ 8,641 $ 15,409 Net income $ 7,364 $ 12,825 Earnings per share: Basic $ 0.98 $ 1.71 Diluted $ 0.97 $ 1.69 The above unaudited pro forma information is presented for illustrative purposes only and may not may

Note 3 - Revenue Recognition

Note 3 - Revenue Recognition	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	( 3 Revenue Recognition The Company recognizes revenue when a customer obtains control of a promised good or service. The amount of revenue recognized reflects the consideration that the Company expects to be entitled to in exchange for promised goods or services. The Company recognizes revenue in accordance with the core principles of ASC 606 1 2 3 4 5 not not Disaggregated Revenue The following table presents the Company’s revenue disaggregated by the major types of goods and services sold to the Company’s customers (in thousands): Three Months Ended Six Months Ended June 30, June 30, Net sales of: 2022 2021 2022 2021 Products $ 89,672 $ 49,466 $ 159,137 $ 96,789 Tooling and Machinery 2,846 332 3,324 744 Engineering services 1,825 857 3,124 1,721 Total net sales $ 94,343 $ 50,655 $ 165,585 $ 99,254 Contract balances Timing of revenue recognition may The following table presents a roll-forward of contract liabilities activity for the six June 30, 2022 2021 Contract Liabilities Six Months Ended June 30, 2022 2021 Deferred revenue - beginning of period $ 4,247 $ 1,887 Increases due to consideration received from customers 3,378 1,869 Revenue recognized (2,013 ) (727 ) Deferred revenue - end of period $ 5,612 $ 3,029 Revenue recognized during the six June 30, 2022 2021 When invoicing occurs after revenue recognition, the Company has contract assets, included within “receivables” on the condensed consolidated balance sheet. The following table presents a roll-forward of contract assets activity for the six June 30, 2022 2021 Contract Assets Six Months Ended June 30, 2022 2021 Unbilled receivables - beginning of period $ 74 $ 271 Increases due to revenue recognized, not invoiced to customers 1,937 935 Decreases due to customer invoicing (1,784 ) (1,008 ) Unbilled receivables - end of period $ 227 $ 198

Note 4 - Supplemental Cash Flow

Note 4 - Supplemental Cash Flow Information	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	( 4 Supplemental Cash Flow Information Six Months Ended June 30, 2022 2021 (in thousands) Cash paid for: Interest $ 1,038 $ 26 Income taxes, net of refunds 5,033 3,112 Non-cash investing and financing activities: Capital additions accrued but not yet paid $ 208 $ 202

Note 5 - Receivables and Allowa

Note 5 - Receivables and Allowance for Credit Losses	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	( 5 Receivables and Allowance for Credit Losses Receivables consist of the following (in thousands): June 30, December 31, 2022 2021 Accounts receivable–trade $ 58,577 $ 39,903 Less allowance for credit losses (664 ) (519 ) Receivables, net $ 57,913 $ 39,384 The Company is exposed to credit losses primarily through sales of products and services. The Company’s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers' trade accounts receivables. Due to the short-term nature of such receivables, the estimate of the amount of accounts receivable that may not The following table provides a roll-forward of the allowance for credit losses that is deducted from accounts receivable to present the net amount expected to be collected as of June 30, 2022 2021 Allowance for Credit Losses Six Months Ended June 30, 2022 2021 Allowance - beginning of period $ 519 $ 484 Provision for expected credit losses 159 88 Amounts written off against the allowance (14 ) (8 ) Allowance - end of period $ 664 $ 564

Note 6 - Fair Value of Financia

Note 6 - Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Fair Value Disclosures [Text Block]	( 6 Fair Value of Financial Instruments Financial instruments recorded at fair value in the consolidated balance sheets, or disclosed at fair value in the footnotes, are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels defined by ASC 820, Fair Value Measurements and Disclosures Level 1 Valued based on unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 Valued based on either directly or indirectly observable prices for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 Valued based on management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. The following table presents the fair value and hierarchy levels, for financial assets that are measured at fair value on a recurring basis (in thousands): June 30, 2022 December 31, 2021 Level 2 Assets (Liabilities): Derivative financial instruments $ 6 $ (176 ) Level 3 Purchase price contingent consideration (Note 2): Accrued contingent consideration (earn-out) $ (15,733 ) $ (9,731 ) Present value of non-competition payments (9,348 ) (8,855 ) Derivative financial instruments consist of an interest rate swap for which fair value is determined through the use of a pricing model that utilizes verifiable inputs such as market interest rates that are observable at commonly quoted intervals for the full term of the swap agreement. In connection with the acquisitions discussed in Note 2, 3 June 30, 2022 three six In connection with the DAS Medical acquisition, the Company has entered into Non-Competition Agreements with the beneficiaries and the Company has agreed to pay additional consideration to the parties to the Non-Competition Agreements, including an aggregate of $10.0 million in payments over the ten €375 three five The Company has financial instruments, such as accounts receivable, accounts payable, and accrued expenses, that are stated at carrying amounts that approximate fair value because of the short maturity of those instruments. The carrying amount of the Company’s long-term debt approximates fair value as the interest rate on the debt approximates the estimated borrowing rate currently available to the Company.

Note 7 - Share-based Compensati

Note 7 - Share-based Compensation	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	( 7 Share-Based Compensation Share-based compensation is measured at the grant date based on the fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). The Company issues share-based awards through several plans that are described in detail in the notes to the consolidated financial statements for the year ended December 31, 2021. Three Months Ended Six Months Ended June 30, June 30, Share-based compensation related to: 2022 2021 2022 2021 Common stock grants $ 100 $ 100 $ 200 $ 200 Stock option grants 60 53 113 105 Restricted Stock Unit Awards ("RSUs") 621 467 1,160 816 Total share-based compensation $ 781 $ 620 $ 1,473 $ 1,121 The total income tax benefit recognized in the condensed consolidated statements of income for share-based compensa‐tion arrangements was approximately $236 thousand and $200 thousand for the three June 30, 2022 2021, six June 30, 2022 2021, Common stock grants The compensation expense for common stock grants during the six June 30, 2022, Stock Option grants The following is a summary of stock option activity under all plans for the six June 30, 2022: Shares Under Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2021 98,671 $ 33.53 Granted 9,876 77.28 Exercised (1,295 ) 16.32 Outstanding at June 30, 2022 107,252 $ 37.77 5.81 $ 4,483 Exercisable at June 30, 2022 97,376 $ 33.76 5.39 $ 4,461 Vested and expected to vest at June 30, 2022 107,252 $ 37.77 $ 5.81 $ 4,483 On June 8, 2022, Expected volatility 34.7% Expected dividends None Risk-free interest rate 2.9% Exercise price $77.28 Expected term (in years) 6.2 Weighted-average grant date fair value $30.37 The stock volatility for each grant is determined based on a review of the experience of the weighted average of historical daily price changes of the Company’s common stock over the expected option term, and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods correspond‐ing with the expected term of the option. The expected term is estimated based on historical option exercise activity. During the six June 30, 2022 2021, six June 30, 2022 2021, Restricted Stock Unit awards The following table summarizes information about RSU activity during the six June 30, 2022: Restricted Stock Units Weighted Average Grant Date Fair Value Outstanding at December 31, 2021 101,168 $ 41.78 Awarded 51,981 74.94 Shares vested (49,575 ) 41.05 Shares forfeited (21 ) 74.75 Outstanding at June 30, 2022 103,553 $ 53.59 At the Company’s discretion, upon vesting, RSU holders are given the option to net-share settle to cover the required minimum withholding tax and the remaining amount is converted into the equivalent number of common shares and issued to the RSU holder. During the six June 30, 2022 2021, As of June 30, 2022,

Note 8 - Inventories

Note 8 - Inventories	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	( 8 Inventories Inventories are stated at the lower of cost (determined using the first first June 30, December 31, 2022 2021 Raw materials $ 32,671 $ 22,184 Work in process 7,297 4,205 Finished goods 10,588 7,047 Total inventory $ 50,556 $ 33,436

Note 9 - Leases

Note 9 - Leases	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	( 9 Leases The Company has operating and finance leases for offices, manufacturing plants, vehicles and certain office and manufacturing equipment. Leases with an initial term of 12 not not ROU assets represent the Company's right to use an underlying asset during the lease term and lease liabilities represent the Company's obligation to make lease payments pursuant to the lease. ROU assets and lease liabilities are recognized at commencement date based on the net present value of fixed lease payments over the lease term. The Company's assumed lease term includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option. ROU assets are also adjusted for any deferred or accrued rent. As the Company's leases do not Six Months Ended June 30, ($ in thousands) 2022 2021 Lease Cost: Finance lease cost: Amortization of right of use assets $ 30 $ 8 Interest on lease liabilities 3 1 Operating lease cost 1,301 598 Variable lease cost 156 116 Short-term lease cost 43 17 Total lease cost $ 1,533 $ 740 Six Months Ended June 30, ($ in thousands) 2022 2021 Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases $ 1,183 $ 608 Financing cash flows from finance leases 32 9 Weighted-average remaining lease term (years): Finance 4.04 5.83 Operating 4.06 1.64 Weighted-average discount rate: Finance 2.10 % 2.26 % Operating 2.76 % 3.99 % The aggregate future lease payments for leases as of June 30, 2022 Finance Operating Remainder of 2022 $ 31 $ 1,230 2023 63 2,256 2024 63 2,234 2025 63 1,963 2026 29 1,694 Thereafter 6 4,432 Total lease payments 255 13,809 Less: Interest (11 ) (1,239 ) Present value of lease liabilities $ 244 $ 12,570

Note 10 - Income Per Share

Note 10 - Income Per Share	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	( 10 Income Per Share Basic income per share is based on the weighted average number of shares of common stock outstanding. Diluted income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalent shares outstanding during each period. The weighted average number of shares used to compute basic and diluted net income per share consisted of the following (in thousands): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Basic weighted average common shares outstanding 7,563 7,527 7,554 7,517 Weighted average common equivalent shares due to restricted stock, stock options and RSUs 45 46 64 58 Diluted weighted average common shares outstanding 7,608 7,573 7,618 7,575 The computation of diluted earnings per share excludes the effect of the potential exercise of stock awards, including stock options, when the average market price of the common stock is lower than the exercise price of the related stock options during the period. These outstanding stock options are not three six June 30, 2022, three six June 30, 2021,

Note 11 - Segment Reporting

Note 11 - Segment Reporting	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	( 11 Segment Reporting The Company consists of a single operating and reportable segment. One customer comprised 20.2% and 17.8% of the Company’s consolidated revenues for the three six June 30, 2022, No 10% 2021. June 30, 2022, one 10% December 31, 2021, no 10% The Company’s products are primarily sold to customers within the Medical, Consumer, Automotive, Aerospace & Defense, Industrial, and Electronics markets. Net sales by market for the three six June 30, 2022 2021 Three Months Ended June 30, Six Months Ended June 30, 2022 2021 (1) 2022 2021 (1) Market Net Sales % Net Sales % Net Sales % Net Sales % Medical $ 74,290 78.7 % $ 32,606 64.4 % $ 126,873 76.6 % $ 62,711 63.2 % Consumer 6,767 7.2 % 6,080 12.0 % 12,545 7.6 % 11,676 11.8 % Automotive 4,351 4.6 % 3,567 7.0 % 8,702 5.3 % 8,214 8.3 % Aerospace & Defense 3,751 4.0 % 4,376 8.6 % 7,507 4.5 % 8,755 8.8 % Industrial 2,665 2.8 % 2,230 4.4 % 5,176 3.0 % 4,345 4.3 % Electronics 2,519 2.7 % 1,796 3.6 % 4,782 3.0 % 3,553 3.6 % Net Sales $ 94,343 100.0 % $ 50,655 100.0 % $ 165,585 100.0 % $ 99,254 100.0 % ( 1 Certain amounts for the three six June 30, 2021

Note 12 - Goodwill and Other In

Note 12 - Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	( 12 Goodwill and Other Intangible Assets The changes in the carrying amount of goodwill for the six June 30, 2022 Goodwill December 31, 2021 $ 107,905 Acquired in Advant Medical business combination (See Note 2) 7,140 DAS working capital adjustment 196 Foreign currency translation (320 ) June 30, 2022 $ 114,921 The carrying values of the Company’s definite lived intangible assets as of June 30, 2022 Intellectual Property / Tradename & Brand Non- Compete Customer List Total Weighted-average amortization period (in years) 11.9 9.3 20 Gross amount $ 7,023 $ 5,484 $ 65,137 $ 77,644 Accumulated amortization (416 ) (658 ) (6,056 ) (7,130 ) Net balance $ 6,607 $ 4,826 $ 59,081 $ 70,514 Amortization expense related to intangible assets was approximately $1.1 million and $0.3 million, respectively, for the three June 30, 2022 2021, six June 30, 2022 2021. June 30, 2022 Remainder of 2022 $ 3,642 2023 4,771 2024 4,764 2025 4,764 2026 4,762 Thereafter 47,811 Total $ 70,514

Note 13 - Other Long-term Liabi

Note 13 - Other Long-term Liabilities	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	( 13 Other Long-Term Liabilities Other long-term liabilities consist of the following (in thousands): June 30, December 31, 2022 2021 Accrued contingent consideration (earn-out) $ 10,733 $ 9,731 Present value of non-competition payments 9,348 8,855 Other 500 676 $ 20,581 $ 19,262

Note 14 - Income Taxes

Note 14 - Income Taxes	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	( 14 Income Taxes The determination of income tax expense in the accompanying unaudited condensed consolidated statements of income is based upon the estimated effective tax rate for the year, adjusted for the impact of any discrete items which are accounted for in the period in which they occur. The Company recorded income tax expense of approximately 23.2% and 24.2% of income before income tax expense for the three June 30, 2022 2021, six June 30, 2022 2021,

Note 15 - Indebtedness

Note 15 - Indebtedness	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	( 15 Indebtedness On December 22, 2021, February 1, 2018. The credit facilities under the Second Amended and Restated Credit Agreement consist of a $40 million secured term loan to the Company and a secured revolving credit facility, under which the Company may December 21, 2026. March 31, 2022. may The Second Amended and Restated Credit Agreement calls for interest determined by the Bloomberg Short-Term Bank Yield Index rate (“BSBY”) plus a margin that ranges from 1.25% to 2.0% or, at the discretion of the Company, the bank’s prime rate less a margin that ranges from .25% At June 30, 2022, June 30, 2022, Long-term debt consists of the following (in thousands): June 30, 2022 Revolving credit facility $ 62,000 Term loan 38,000 Total long-term debt 100,000 Current portion (4,000 ) Long-term debt, excluding current portion $ 96,000 Future maturities of long-term debt at June 30, 2022 Term Loan Revolving credit facility Total Remainder of 2022 $ 2,000 $ - $ 2,000 2023 $ 4,000 $ - $ 4,000 2024 $ 4,000 $ - $ 4,000 2025 $ 4,000 $ - $ 4,000 2026 $ 24,000 $ 62,000 $ 86,000 $ 38,000 $ 62,000 $ 100,000 Derivative Financial Instruments The Company used interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on certain of its variable-rate debt instruments. The Company does not not The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may three The notional amount was approximately $7.1 million at June 30, 2022. June 30, 2022 December 31, 2021 three six June 30, 2022. 2021, As the Company has paid the remaining balance of the term loan that was associated with the swap in its entirety, there is no February 1, 2023.

Note 16 - Subsequent Event

Note 16 - Subsequent Event	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	( 16 Subsequent Event On July 26, 2022, December 31, 2021.

Note 2 - Acquisitions (Tables)

Note 2 - Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Fair value of considerations transferred Cash paid at closing $ 23,608 Other liability 395 Cash from Advant (2,840 ) Total consideration $ 21,163 Purchase price allocation Accounts receivable $ 2,299 Inventory 2,410 Other current assets 213 Property, plant, and equipment 5,704 Customer contracts & relationships 2,925 Intellectual property 2,127 Non-compete agreement 259 Lease right of use assets 289 Other assets 42 Goodwill 7,139 Total identifiable assets $ 23,407 Accounts payable (772 ) Accrued expenses (668 ) Income taxes (66 ) Deferred taxes (449 ) Lease liabilities (289 ) Net assets acquired $ 21,163 Cash paid at closing $ 95,000 Contingent liability (Earn-out) 5,188 Non-compete agreements 8,855 Cash from DAS (8,316 ) Working capital adjustment (115 ) Total consideration $ 100,612 Purchase price allocation Accounts receivable $ 2,351 Inventory 7,570 Other current assets 68 Property, plant, and equipment 3,314 Customer contracts & relationships 36,730 Intellectual property 2,380 Non-compete agreement 4,697 Lease right of use assets 1,221 Goodwill 51,985 Total identifiable assets $ 110,316 Accounts payable (5,238 ) Accrued expenses (3,238 ) Deferred revenue (7 ) Lease liabilities (1,221 ) Net assets acquired $ 100,612 Fair value of considerations transferred Cash paid at closing $ 9,766 Contingent liability (Earn-out) 4,543 Other liability 500 Cash from Contech (266 ) Total consideration $ 14,543 Purchase price allocation Accounts receivable $ 2,851 Inventory 2,320 Other current assets 37 Property, plant, and equipment 1,170 Customer contracts & relationships 3,043 Intellectual property 2,247 Non-compete agreement 86 Lease right of use assets 1,523 Goodwill 4,278 Total identifiable assets $ 17,555 Accounts payable (1,015 ) Accrued expenses (414 ) Deferred revenue (60 ) Lease liabilities (1,523 ) Net assets acquired $ 14,543
Business Acquisition, Pro Forma Information [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2021 2022 2021 (Unaudited) (Unaudited) (Unaudited) Sales $ 56,203 $ 169,812 $ 110,079 Operating Income $ 6,666 $ 19,302 $ 12,663 Net Income $ 5,027 $ 14,341 $ 9,666 Earnings per share: Basic $ 0.67 $ 1.90 $ 1.29 Diluted $ 0.66 $ 1.88 $ 1.28 Three-month Period Ended June 30, 2021 Six-month Period Ended June 30, 2021 (Unaudited) (Unaudited) Sales $ 68,741 $ 132,603 Operating income $ 8,641 $ 15,409 Net income $ 7,364 $ 12,825 Earnings per share: Basic $ 0.98 $ 1.71 Diluted $ 0.97 $ 1.69

Note 3 - Revenue Recognition (T

Note 3 - Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, Net sales of: 2022 2021 2022 2021 Products $ 89,672 $ 49,466 $ 159,137 $ 96,789 Tooling and Machinery 2,846 332 3,324 744 Engineering services 1,825 857 3,124 1,721 Total net sales $ 94,343 $ 50,655 $ 165,585 $ 99,254
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Contract Liabilities Six Months Ended June 30, 2022 2021 Deferred revenue - beginning of period $ 4,247 $ 1,887 Increases due to consideration received from customers 3,378 1,869 Revenue recognized (2,013 ) (727 ) Deferred revenue - end of period $ 5,612 $ 3,029 Contract Assets Six Months Ended June 30, 2022 2021 Unbilled receivables - beginning of period $ 74 $ 271 Increases due to revenue recognized, not invoiced to customers 1,937 935 Decreases due to customer invoicing (1,784 ) (1,008 ) Unbilled receivables - end of period $ 227 $ 198

Note 4 - Supplemental Cash Fl_2

Note 4 - Supplemental Cash Flow Information (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	Six Months Ended June 30, 2022 2021 (in thousands) Cash paid for: Interest $ 1,038 $ 26 Income taxes, net of refunds 5,033 3,112 Non-cash investing and financing activities: Capital additions accrued but not yet paid $ 208 $ 202

Note 5 - Receivables and Allo_2

Note 5 - Receivables and Allowance for Credit Losses (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	June 30, December 31, 2022 2021 Accounts receivable–trade $ 58,577 $ 39,903 Less allowance for credit losses (664 ) (519 ) Receivables, net $ 57,913 $ 39,384
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	Allowance for Credit Losses Six Months Ended June 30, 2022 2021 Allowance - beginning of period $ 519 $ 484 Provision for expected credit losses 159 88 Amounts written off against the allowance (14 ) (8 ) Allowance - end of period $ 664 $ 564

Note 6 - Fair Value of Financ_2

Note 6 - Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	June 30, 2022 December 31, 2021 Level 2 Assets (Liabilities): Derivative financial instruments $ 6 $ (176 ) Level 3 Purchase price contingent consideration (Note 2): Accrued contingent consideration (earn-out) $ (15,733 ) $ (9,731 ) Present value of non-competition payments (9,348 ) (8,855 )

Note 7 - Share-based Compensa_2

Note 7 - Share-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Employee Service Share Based Compensation Allocation of Recognized Period Costs, By Award Type [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, Share-based compensation related to: 2022 2021 2022 2021 Common stock grants $ 100 $ 100 $ 200 $ 200 Stock option grants 60 53 113 105 Restricted Stock Unit Awards ("RSUs") 621 467 1,160 816 Total share-based compensation $ 781 $ 620 $ 1,473 $ 1,121
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Shares Under Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at December 31, 2021 98,671 $ 33.53 Granted 9,876 77.28 Exercised (1,295 ) 16.32 Outstanding at June 30, 2022 107,252 $ 37.77 5.81 $ 4,483 Exercisable at June 30, 2022 97,376 $ 33.76 5.39 $ 4,461 Vested and expected to vest at June 30, 2022 107,252 $ 37.77 $ 5.81 $ 4,483
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Expected volatility 34.7% Expected dividends None Risk-free interest rate 2.9% Exercise price $77.28 Expected term (in years) 6.2 Weighted-average grant date fair value $30.37
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	Restricted Stock Units Weighted Average Grant Date Fair Value Outstanding at December 31, 2021 101,168 $ 41.78 Awarded 51,981 74.94 Shares vested (49,575 ) 41.05 Shares forfeited (21 ) 74.75 Outstanding at June 30, 2022 103,553 $ 53.59

Note 8 - Inventories (Tables)

Note 8 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, December 31, 2022 2021 Raw materials $ 32,671 $ 22,184 Work in process 7,297 4,205 Finished goods 10,588 7,047 Total inventory $ 50,556 $ 33,436

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Lease, Cost [Table Text Block]	Six Months Ended June 30, ($ in thousands) 2022 2021 Lease Cost: Finance lease cost: Amortization of right of use assets $ 30 $ 8 Interest on lease liabilities 3 1 Operating lease cost 1,301 598 Variable lease cost 156 116 Short-term lease cost 43 17 Total lease cost $ 1,533 $ 740 Six Months Ended June 30, ($ in thousands) 2022 2021 Cash paid for amounts included in measurement of lease liabilities: Operating cash flows from operating leases $ 1,183 $ 608 Financing cash flows from finance leases 32 9 Weighted-average remaining lease term (years): Finance 4.04 5.83 Operating 4.06 1.64 Weighted-average discount rate: Finance 2.10 % 2.26 % Operating 2.76 % 3.99 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Finance Operating Remainder of 2022 $ 31 $ 1,230 2023 63 2,256 2024 63 2,234 2025 63 1,963 2026 29 1,694 Thereafter 6 4,432 Total lease payments 255 13,809 Less: Interest (11 ) (1,239 ) Present value of lease liabilities $ 244 $ 12,570

Note 10 - Income Per Share (Tab

Note 10 - Income Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Basic weighted average common shares outstanding 7,563 7,527 7,554 7,517 Weighted average common equivalent shares due to restricted stock, stock options and RSUs 45 46 64 58 Diluted weighted average common shares outstanding 7,608 7,573 7,618 7,575

Note 11 - Segment Reporting (Ta

Note 11 - Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 (1) 2022 2021 (1) Market Net Sales % Net Sales % Net Sales % Net Sales % Medical $ 74,290 78.7 % $ 32,606 64.4 % $ 126,873 76.6 % $ 62,711 63.2 % Consumer 6,767 7.2 % 6,080 12.0 % 12,545 7.6 % 11,676 11.8 % Automotive 4,351 4.6 % 3,567 7.0 % 8,702 5.3 % 8,214 8.3 % Aerospace & Defense 3,751 4.0 % 4,376 8.6 % 7,507 4.5 % 8,755 8.8 % Industrial 2,665 2.8 % 2,230 4.4 % 5,176 3.0 % 4,345 4.3 % Electronics 2,519 2.7 % 1,796 3.6 % 4,782 3.0 % 3,553 3.6 % Net Sales $ 94,343 100.0 % $ 50,655 100.0 % $ 165,585 100.0 % $ 99,254 100.0 %

Note 12 - Goodwill and Other _2

Note 12 - Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Goodwill [Table Text Block]	Goodwill December 31, 2021 $ 107,905 Acquired in Advant Medical business combination (See Note 2) 7,140 DAS working capital adjustment 196 Foreign currency translation (320 ) June 30, 2022 $ 114,921
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Intellectual Property / Tradename & Brand Non- Compete Customer List Total Weighted-average amortization period (in years) 11.9 9.3 20 Gross amount $ 7,023 $ 5,484 $ 65,137 $ 77,644 Accumulated amortization (416 ) (658 ) (6,056 ) (7,130 ) Net balance $ 6,607 $ 4,826 $ 59,081 $ 70,514
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Remainder of 2022 $ 3,642 2023 4,771 2024 4,764 2025 4,764 2026 4,762 Thereafter 47,811 Total $ 70,514

Note 13 - Other Long-term Lia_2

Note 13 - Other Long-term Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Other Noncurrent Liabilities [Table Text Block]	June 30, December 31, 2022 2021 Accrued contingent consideration (earn-out) $ 10,733 $ 9,731 Present value of non-competition payments 9,348 8,855 Other 500 676 $ 20,581 $ 19,262

Note 15 - Indebtedness (Tables)

Note 15 - Indebtedness (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Debt [Table Text Block]	June 30, 2022 Revolving credit facility $ 62,000 Term loan 38,000 Total long-term debt 100,000 Current portion (4,000 ) Long-term debt, excluding current portion $ 96,000
Schedule of Maturities of Long-Term Debt [Table Text Block]	Term Loan Revolving credit facility Total Remainder of 2022 $ 2,000 $ - $ 2,000 2023 $ 4,000 $ - $ 4,000 2024 $ 4,000 $ - $ 4,000 2025 $ 4,000 $ - $ 4,000 2026 $ 24,000 $ 62,000 $ 86,000 $ 38,000 $ 62,000 $ 100,000

Note 2 - Acquisitions (Details

Note 2 - Acquisitions (Details Textual) € in Thousands, $ in Thousands							3 Months Ended		6 Months Ended			12 Months Ended	18 Months Ended
	Mar. 17, 2022 USD ($)	Mar. 16, 2022 USD ($)	Mar. 16, 2022 EUR (€)	Dec. 22, 2021 USD ($)	Dec. 21, 2021 USD ($)	Oct. 12, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Jun. 30, 2022 USD ($)
Business Combination, Acquisition Related Costs							$ 242	$ 0	$ 1,017		$ 0
Advant Medical [Member]
Business Acquisition, Percentage of Voting Interests Acquired		100%	100%
Payments to Acquire Businesses, Net of Cash Acquired, Total			€ 19,000						20,768		0
Payments to Acquire Businesses, Gross	$ 23,608	$ 21,200
Business Combination, Acquisition Related Costs									779		749	$ 30
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual									6,800
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual									700
DAS Medical [Member]
Business Acquisition, Percentage of Voting Interests Acquired				100%
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 66,700					(115)		$ 0
Payments to Acquire Businesses, Gross					$ 95,000
Business Combination, Acquisition Related Costs									$ 155			293	$ 448
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				20,000
Business Combination, Working Capital Adjustment				(115,000)	$ 115
DAS Medical [Member] | Goodwill Agreement [Member]
Payments to Acquire Businesses, Gross				20,000
DAS Medical [Member] | Non-Competition Agreements [Member]
Payments to Acquire Businesses, Gross				$ 10,000						€ 375
Business Combination, Agreement Term (Year)				10 years					5 years	5 years
Contech Medical, Inc [Member]
Business Acquisition, Percentage of Voting Interests Acquired						100%
Payments to Acquire Businesses, Net of Cash Acquired, Total						$ 9,500
Payments to Acquire Businesses, Gross						9,766
Business Combination, Acquisition Related Costs									$ 113			$ 40	$ 153
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						5,000
Business Combination, Contingent Consideration, Liability, Total						$ 500

Note 2 - Acquisitions - Assets

Note 2 - Acquisitions - Assets Acquires and Liabilities Assumed (Details) - USD ($) $ in Thousands	Mar. 17, 2022	Mar. 16, 2022	Dec. 22, 2021	Dec. 21, 2021	Oct. 12, 2021	Jun. 30, 2022	Dec. 31, 2021
Goodwill						$ 114,921	$ 107,905
DAS Medical [Member]
Cash paid at closing				$ 95,000
Cash from Advant				(8,316)
Total consideration				100,612
Accounts receivable				2,351
Inventory				7,570
Other current assets				68
Property, plant, and equipment				3,314
Lease right of use assets				1,221
Goodwill				51,985
Total identifiable assets				110,316
Accounts payable				(5,238)
Accrued expenses				(3,238)
Lease liabilities				(1,221)
Net assets acquired				100,612
Contingent liability (Earn-out)				5,188
Non-compete agreements				8,855
Working capital adjustment			$ 115,000	(115)
Deferred revenue				(7)
DAS Medical [Member] | Customer Contracts and Relationships [Member]
Customer contracts & relationships				36,730
DAS Medical [Member] | Intellectual Property [Member]
Customer contracts & relationships				2,380
DAS Medical [Member] | Noncompete Agreements [Member]
Customer contracts & relationships				$ 4,697
Advant Medical [Member]
Cash paid at closing	$ 23,608	$ 21,200
Other liability	395
Cash from Advant	(2,840)
Total consideration	21,163
Accounts receivable	2,299
Inventory	2,410
Other current assets	213
Property, plant, and equipment	5,704
Lease right of use assets	289
Other assets	42
Goodwill	7,139
Total identifiable assets	23,407
Accounts payable	(772)
Accrued expenses	(668)
Income taxes	(66)
Deferred taxes	(449)
Lease liabilities	(289)
Net assets acquired	21,163
Advant Medical [Member] | Customer Contracts and Relationships [Member]
Customer contracts & relationships	2,925
Advant Medical [Member] | Intellectual Property [Member]
Customer contracts & relationships	2,127
Advant Medical [Member] | Noncompete Agreements [Member]
Customer contracts & relationships	$ 259
Contech Medical, Inc [Member]
Cash paid at closing					$ 9,766
Other liability					500
Cash from Advant					(266)
Total consideration					14,543
Accounts receivable					2,851
Inventory					2,320
Other current assets					37
Property, plant, and equipment					1,170
Lease right of use assets					1,523
Goodwill					4,278
Total identifiable assets					17,555
Accounts payable					(1,015)
Accrued expenses					(414)
Lease liabilities					(1,523)
Net assets acquired					14,543
Contingent liability (Earn-out)					4,543
Deferred revenue					(60)
Contech Medical, Inc [Member] | Customer Contracts and Relationships [Member]
Customer contracts & relationships					3,043
Contech Medical, Inc [Member] | Intellectual Property [Member]
Customer contracts & relationships					2,247
Contech Medical, Inc [Member] | Noncompete Agreements [Member]
Customer contracts & relationships					$ 86

Note 2 - Acquisition - Pro Form

Note 2 - Acquisition - Pro Forma Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Advant Medical [Member]
Sales	$ 56,203		$ 169,812	$ 110,079
Operating Income	6,666		19,302	12,663
Net Income	$ 5,027		$ 14,341	$ 9,666
Basic (in dollars per share)	$ 0.67		$ 1.90	$ 1.29
Diluted (in dollars per share)	$ 0.66		$ 1.88	$ 1.28
Contech Medical, Inc and DAS Medical [Member]
Sales		$ 68,741		$ 132,603
Operating Income		8,641		15,409
Net Income		$ 7,364		$ 12,825
Basic (in dollars per share)		$ 0.98		$ 1.71
Diluted (in dollars per share)		$ 0.97		$ 1.69

Note 3 - Revenue Recognition (D

Note 3 - Revenue Recognition (Details Textual) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Deferred Revenue [Member]
Contract with Customer, Liability, Revenue Recognized	$ 1.8	$ 0.4

Note 3 - Revenue Recognition -

Note 3 - Revenue Recognition - Revenue Disaggregated by the Major Types of Goods and Services Sold (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net sales	$ 94,343	$ 50,655	$ 165,585	$ 99,254
Product [Member]
Net sales	89,672	49,466	159,137	96,789
Tooling and Machinery [Member]
Net sales	2,846	332	3,324	744
Engineering and Development [Member]
Net sales	$ 1,825	$ 857	$ 3,124	$ 1,721

Note 3 - Revenue Recognition _2

Note 3 - Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Deferred revenue	$ 4,247	$ 1,887
Increases due to consideration received from customers	3,378	1,869
Revenue recognized	(2,013)	(727)
Deferred revenue	5,612	3,029
Unbilled receivables - beginning of period	74	271
Increases due to revenue recognized, not invoiced to customers	1,937	935
Decreases due to customer invoicing	(1,784)	(1,008)
Unbilled receivables - end of period	$ 227	$ 198

Note 4 - Supplemental Cash Fl_3

Note 4 - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash paid for:
Interest	$ 1,038	$ 26
Income taxes, net of refunds	5,033	3,112
Non-cash investing and financing activities:
Capital additions accrued but not yet paid	$ 208	$ 202

Note 5 - Receivables and Allo_3

Note 5 - Receivables and Allowance for Credit Losses - Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accounts receivable–trade	$ 58,577	$ 39,903
Less allowance for credit losses	(664)	(519)
Receivables, net	$ 57,913	$ 39,384

Note 5 - Receivables and Allo_4

Note 5 - Receivables and Allowance for Credit Losses - Summary of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Allowance - beginning of period	$ 519	$ 484
Provision for expected credit losses	159	88
Amounts written off against the allowance	(14)	(8)
Allowance - end of period	$ 664	$ 564

Note 6 - Fair Value of Financ_3

Note 6 - Fair Value of Financial Instruments (Details Textual) € in Thousands, $ in Thousands			3 Months Ended		6 Months Ended
	Dec. 22, 2021 USD ($)	Dec. 21, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			$ (6,002)	$ 0	$ (6,002)		$ 0
Contech Medical, Inc and DAS Medical [Member]
Business Combination, Consideration Transferred, Liabilities Incurred					25,000
Business Combination, Contingent Consideration, Liability, Total			15,700		$ 15,700			$ 9,700
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			$ 6,000
DAS Medical [Member]
Business Combination, Consideration Transferred, Liabilities Incurred		$ 5,188
Payments to Acquire Businesses, Gross		$ 95,000
DAS Medical [Member] | Non-Competition Agreements [Member]
Payments to Acquire Businesses, Gross	$ 10,000					€ 375
Business Combination, Agreement Term (Year)	10 years				5 years	5 years
Business Combination, Agreement Term, Final Three Years (Year)					3 years	3 years

Note 6 - Fair Value of Financ_4

Note 6 - Fair Value of Financial Instruments - Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Inputs, Level 2 [Member]
Derivative financial instruments	$ 6	$ (176)
Fair Value, Inputs, Level 3 [Member]
Accrued contingent consideration (earn-out)	15,733	9,731
Present value of non-competition payments	$ 9,348	$ 8,855

Note 7 - Share-based Compensa_3

Note 7 - Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Jun. 08, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share Price (in dollars per share)	$ 77.28
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 4,700		$ 4,700
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				2 years 9 months 18 days
Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	9,876
Share-Based Payment Arrangement [Member]
Share-Based Payment Arrangement, Expense, Tax Benefit		$ 236	$ 200	$ 617	$ 441
Employee and Nonemployee Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				9,876
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value				$ 72	164
Proceeds from Stock Options Exercised				$ 21	$ 162
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)				0	0
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)				19,425	14,122
Shares Paid for Tax Withholding for Share Based Compensation Market Price (in dollars per share)				$ 67.05	$ 52.47

Note 7 - Share-based Compensa_4

Note 7 - Share-based Compensation - Compensation Cost (Details) - Selling, General and Administrative Expenses [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based compensation	$ 781	$ 620	$ 1,473	$ 1,121
Common Stock [Member]
Share-based compensation	100	100	200	200
Employee and Nonemployee Stock Option [Member]
Share-based compensation	60	53	113	105
Restricted Stock Units (RSUs) [Member]
Share-based compensation	$ 621	$ 467	$ 1,160	$ 816

Note 7 - Share-based Compensa_5

Note 7 - Share-based Compensation - Summary of Stock Option Activity (Details) - Employee and Nonemployee Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022
Outstanding, shares under options (in shares)	98,671
Outstanding, weighted average exercise price (in dollars per share)	$ 33.53
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	9,876
Granted (in dollars per share)	$ 77.28
Exercised, shares under options (in shares)	(1,295)
Granted, weighted average exercise price (in dollars per share)	$ 16.32
Outstanding, shares under options (in shares)	107,252
Outstanding, weighted average exercise price (in dollars per share)	$ 37.77
Outstanding, weighted average remaining contractual life (Year)	5 years 9 months 21 days
Outstanding, aggregate intrinsic value	$ 4,483
Exercisable, shares under options (in shares)	97,376
Exercisable, weighted average exercise price (in dollars per share)	$ 33.76
Exercisable, weighted average remaining contractual life (Year)	5 years 4 months 20 days
Exercisable, aggregate intrinsic value	$ 4,461
Vested and expected to vest, shares under options (in shares)	107,252
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 37.77
Vested and expected to vest, weighted average remaining contractual life (Year)	5 years 9 months 21 days
Vested and expected to vest, aggregate intrinsic value	$ 4,483

Note 7 - Share-based Compensa_6

Note 7 - Share-based Compensation - Black-Scholes Option Pricing Model (Details)	Jun. 08, 2022 $ / shares
Expected volatility	34.70%
Expected dividends	0%
Risk-free interest rate	2.90%
Exercise price (in dollars per share)	$ 77.28
Expected term (in years) (Year)	6 years 2 months 12 days
Weighted-average grant date fair value (in dollars per share)	$ 30.37

Note 7 - Share-based Compensa_7

Note 7 - Share-based Compensation - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2022 $ / shares shares
Outstanding, restricted stock units (in shares) | shares	101,168
Outstanding, weighted average award date fair value (in dollars per share) | $ / shares	$ 41.78
Awarded, restricted stock units (in shares) | shares	51,981
Awarded, weighted average award date fair value (in dollars per share) | $ / shares	$ 74.94
Shares vested, restricted stock units (in shares) | shares	(49,575)
Shares vested, weighted average award date fair value (in dollars per share) | $ / shares	$ 41.05
Shares forfeited (in shares) | shares	(21)
Shares forfeited (in dollars per share) | $ / shares	$ 74.75
Outstanding, restricted stock units (in shares) | shares	103,553
Outstanding, weighted average award date fair value (in dollars per share) | $ / shares	$ 53.59

Note 8 - Inventories - Summary

Note 8 - Inventories - Summary of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Raw materials	$ 32,671	$ 22,184
Work in process	7,297	4,205
Finished goods	10,588	7,047
Total inventory	$ 50,556	$ 33,436

Note 9 - Leases - Lease Cost (D

Note 9 - Leases - Lease Cost (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Lease Cost:
Amortization of right of use assets	$ 30	$ 8
Interest expense on finance leases	3	1
Operating lease cost	1,301	598
Variable lease cost	156	116
Short-term lease cost	43	17
Total lease cost	1,533	740
Operating cash flows from operating leases	1,183	608
Financing cash flows from finance leases	$ 32	$ 9
Finance (Year)	4 years 14 days	5 years 9 months 29 days
Operating (Year)	4 years 21 days	1 year 7 months 20 days
Finance	2.10%	2.26%
Operating	2.76%	3.99%

Note 9 - Leases - Aggregate Fut

Note 9 - Leases - Aggregate Future Lease Payments (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Remainder of 2022. finance	$ 31
Remainder of 2022, operating	1,230
2023, finance	63
2023, operating	2,256
2024, finance	63
2024, operating	2,234
2025, finance	63
2025, operating	1,963
2026, finance	29
2026, operating	1,694
Thereafter, finance	6
Thereafter, operating	4,432
Total lease payments, finance	255
Total lease payments, operating	13,809
Less: Interest, finance	(11)
Less: Interest, operating	(1,239)
Present value of lease liabilities, finance	244
Present value of lease liabilities, operating	$ 12,570

Note 10 - Income Per Share (Det

Note 10 - Income Per Share (Details Textual) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	9,876	10,716	9,876	10,716

Note 10 - Net Income Per Share

Note 10 - Net Income Per Share - Weighted Average Number of Shares Used to Compute Net EPS (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Basic weighted average common shares outstanding (in shares)	7,563	7,527	7,554	7,517
Weighted average common equivalent shares due to restricted stock, stock options and RSUs (in shares)	45	46	64	58
Diluted weighted average common shares outstanding (in shares)	7,608	7,573	7,618	7,575

Note 11 - Segment Reporting (De

Note 11 - Segment Reporting (Details Textual)	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage	20.20%	17.80%

Note 11 - Segment Reporting - N

Note 11 - Segment Reporting - Net Sales by Market (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net sales	$ 94,343	$ 50,655	$ 165,585	$ 99,254
Percentage of concentration risk	100%	100%	100%	100%
Medical [Member]
Net sales	$ 74,290	$ 32,606	$ 126,873	$ 62,711
Percentage of concentration risk	78.70%	64.40%	76.60%	63.20%
Consumer [Member]
Net sales	$ 6,767	$ 6,080	$ 12,545	$ 11,676
Percentage of concentration risk	7.20%	12%	7.60%	11.80%
Automotive [Member]
Net sales	$ 4,351	$ 3,567	$ 8,702	$ 8,214
Percentage of concentration risk	4.60%	7%	5.30%	8.30%
Aerospace & Defense [Member]
Net sales	$ 3,751	$ 4,376	$ 7,507	$ 8,755
Percentage of concentration risk	4%	8.60%	4.50%	8.80%
Industrial [Member]
Net sales	$ 2,665	$ 2,230	$ 5,176	$ 4,345
Percentage of concentration risk	2.80%	4.40%	3%	4.30%
Electronics [Member]
Net sales	$ 2,519	$ 1,796	$ 4,782	$ 3,553
Percentage of concentration risk	2.70%	3.60%	3%	3.60%

Note 12 - Goodwill and Other _3

Note 12 - Goodwill and Other Intangible Assets (Details Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Amortization of Intangible Assets	$ 1.1	$ 0.3	$ 2.1	$ 0.6

Note 12 - Goodwill and Other _4

Note 12 - Goodwill and Other Intangible Assets - Changes in Carrying Amount of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Balance	$ 107,905
Acquired in Advant Medical business combination (See Note 2)	7,140
DAS working capital adjustment	196
Foreign currency translation	(320)
Balance	$ 114,921

Note 12 - Goodwill and Other _5

Note 12 - Goodwill and Other Intangible Assets - Definite-lived Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Gross amount	$ 77,644
Accumulated amortization	(7,130)
Net balance	$ 70,514	$ 67,585
Intellectual Property/ Tradename and Brand [Member]
Weighted-average amortization period (in years) (Year)	11 years 10 months 24 days
Gross amount	$ 7,023
Accumulated amortization	(416)
Net balance	$ 6,607
Noncompete Agreements [Member]
Weighted-average amortization period (in years) (Year)	9 years 3 months 18 days
Gross amount	$ 5,484
Accumulated amortization	(658)
Net balance	$ 4,826
Customer Lists [Member]
Weighted-average amortization period (in years) (Year)	20 years
Gross amount	$ 65,137
Accumulated amortization	(6,056)
Net balance	$ 59,081

Note 12 - Goodwill and Other _6

Note 12 - Goodwill and Other Intangible Assets - Future Amortization of Intangible Assets (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Remainder of 2022	$ 3,642
2023	4,771
2024	4,764
2025	4,764
2026	4,762
Thereafter	47,811
Total	$ 70,514

Note 13 - Other Long-term Lia_3

Note 13 - Other Long-term Liabilities - Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accrued contingent consideration (earn-out)	$ 10,733	$ 9,731
Present value of non-competition payments	9,348	8,855
Other	500	676
Other Liabilities, Noncurrent	$ 20,581	$ 19,262

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Effective Income Tax Rate Reconciliation, Percent, Total	23.20%	24.20%	22.10%	22.90%

Note 15 - Indebtedness (Details

Note 15 - Indebtedness (Details Textual) - USD ($)			3 Months Ended		6 Months Ended
	Dec. 22, 2021	Feb. 01, 2018	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Long-Term Debt, Total			$ 100,000,000		$ 100,000,000
Interest Rate Swap [Member]
Derivative, Notional Amount		$ 20,000,000	7,100,000		7,100,000
Derivative, Term of Contract (Year)		5 years
Derivative, Fixed Interest Rate		2.70%
Interest Rate Swap [Member] | Other Nonoperating Income (Expense) [Member]
Derivative, Gain (Loss) on Derivative, Net, Total			67,000	$ 64,000	182,000	$ 144,000
Interest Rate Swap [Member] | Other Assets [Member]
Derivative, Fair Value, Net, Total			6,000		6,000
Interest Rate Swap [Member] | Other Current Liabilities [Member]
Derivative, Fair Value, Net, Total			(176,000)		(176,000)
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member]
Debt Instrument, Face Amount	$ 130,000,000
Long-Term Debt, Total			100,000,000		100,000,000
Letters of Credit Outstanding, Amount			$ 700,000		$ 700,000
Debt Instrument, Interest Rate, Stated Percentage			3.40%		3.40%
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member] | Bloomberg Short-term Bank Yield Index Rate [Member] | Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate	1.25%
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member] | Bloomberg Short-term Bank Yield Index Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	2%
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member] | Prime Rate [Member] | Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate	0.25%
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member] | Secured Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 90,000,000
Subsidiary Guarantors [Member] | Second Amended and Restated Credit Agreement [Member] | Secured Term Loan [Member]
Debt Instrument, Face Amount	40,000,000
Debt Instrument, Periodic Payment, Principal	$ 1,000,000

Note 15 - Indebtedness - Long-t

Note 15 - Indebtedness - Long-term Debt (Details) - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Total long-term debt	$ 100
Current portion	(4)	$ (4)
Long-term debt, excluding current portion	96	$ 71
Term Loan [Member]
Total long-term debt	38
Revolving Credit Facility [Member] | Line of Credit [Member]
Total long-term debt	$ 62

Note 15 - Indebtedness - Future

Note 15 - Indebtedness - Future Maturities of Long-term Debt (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Remainder of 2022	$ 2,000
2023	4,000
2024	4,000
2025	4,000
2026	86,000
Long-Term Debt, Total	100,000
Line of Credit [Member] | Revolving Credit Facility [Member]
Remainder of 2022	0
2023	0
2024	0
2025	0
2026	62,000
Long-Term Debt, Total	62,000
Term Loan [Member]
Remainder of 2022	2,000
2023	4,000
2024	4,000
2025	4,000
2026	24,000
Long-Term Debt, Total	$ 38,000

Note 16 - Subsequent Event (Det

Note 16 - Subsequent Event (Details Textual) - molded fiber business (“MFT”) and related real estate in Iowa [Member] - Discontinued Operations, Disposed of by Sale [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Jul. 26, 2022
Disposal Group, Including Discontinued Operation, Revenue	$ 21.3
Subsequent Event [Member]
Disposal Group, Including Discontinued Operation, Consideration		$ 32